title: Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
abstract: Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early prediction of response to imatinib cannot be anticipated. We used a standardized quantitative reverse-transcriptase polymerase chain reaction (QRT-PCR) for BCR-ABL transcripts on 191 out of 200 late-chronic phase CML patients enrolled in a phase II clinical trial with imatinib 400 mg/day. Bone marrow samples were collected before treatment, after 12, 20 and at the end of study treatment (52 weeks) while peripheral blood samples were obtained after 2, 3, 6, 10, 14, 20 and 52 weeks of therapy. The amount of BCR-ABL transcript was expressed as the ratio of BCR-ABL to beta2-microglobulin (beta2M). We show that, following initiation of imatinib, the early BCR-ABL level trends in both bone marrow and peripheral blood samples made it possible to predict the subsequent cytogenetic outcome and response. We propose this method as the method of choice for monitoring patients on imatinib therapy. QRT-PCR studies may be able to identify degrees of molecular response that predict both complete cytogenetic response and long term stability, as well as patterns of response that provide an early indication of relapse and imatinib resistance.
authors.affiliation: Institute of Hematology and Medical Oncology L. and A. Seràgnoli, University of Bologna, Bologna, Italy. gmartino@kaiser.alma.unibo.it
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: I
authors.initials: I
authors.lastname: Iacobucci
authors.forename: G
authors.initials: G
authors.lastname: Rosti
authors.forename: F
authors.initials: F
authors.lastname: Pane
authors.forename: M
authors.initials: M
authors.lastname: Amabile
authors.forename: F
authors.initials: F
authors.lastname: Castagnetti
authors.forename: D
authors.initials: D
authors.lastname: Cilloni
authors.forename: S
authors.initials: S
authors.lastname: Soverini
authors.forename: N
authors.initials: N
authors.lastname: Testoni
authors.forename: G
authors.initials: G
authors.lastname: Specchia
authors.forename: S
authors.initials: S
authors.lastname: Merante
authors.forename: A
authors.initials: A
authors.lastname: Zaccaria
authors.forename: F
authors.initials: F
authors.lastname: Frassoni
authors.forename: G
authors.initials: G
authors.lastname: Saglio
authors.forename: M
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics*; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl